Suzhou Basecare Medical, China's Leading PGT Company, Surges Over 10% as JPMorgan and Other Institutions Increase Stakes

Source: BioExplorer

According to HKEX data, JPMorgan Chase increased its stake in Beikang Medical-B (02170-HK) by 461,900 shares at an average price of HK$28.3333 per share, involving approximately HK$13.0864 million. Following the increase, JPMorgan’s latest holding stands at 7.797 million shares, with its shareholding ratio rising from 9.90% to 10.52%. This move by JPMorgan undoubtedly reflects the long-term optimism of institutional investors toward Beikang Medical, the “first stock in assisted reproductive genetic testing.”

J.P. Morgan Asset Management, a globally leading asset management group with over 150 years of history and an annual research budget exceeding USD 320 million, allocates 25% of its global assets under management to equity investments. In recent years, its Asian investment strategy has focused on the Greater China region, specifically targeting sectors such as new consumer trends, internet, and healthcare. As a long-term fund with extensive industry investment experience and insightful capabilities, it has been actively building positions in the healthcare sector. Following its listing in Hong Kong, Beikang Medical has attracted position-building from multiple top-tier international funds.

Behind the precipitous decline in birth rates and the rising prevalence of infertility, assisted reproductive technology (ART) has benefited from this large patient population, emerging as a breakthrough solution to the challenges of population development and becoming a “new growth hotspot.” Factors such as the continuous rise in the age at first marriage, advanced maternal age, environmental pollution, and unhealthy lifestyles will all bring significant tailwinds to the future market development of ART, a golden track. In 2018, the prevalence of infertility in China exceeded the average level of developed countries, reaching 16%, and is projected to continue rising to 18.2% by 2023.

China currently has a stock of 47.7 million patients with infertility, among whom approximately 70%-80% can be treated through interventions such as lifestyle guidance and pharmacotherapy. The remaining 20% of infertile couples must rely on assisted reproductive technology (ART) to achieve pregnancy, resulting in an estimated potential addressable market of around 10 million individuals in China. Despite the vast market potential for ART, the current penetration rate in China is only 7%, significantly lower than the 30.2% level in the United States. Driven by rising per capita disposable income, the growing emphasis on eugenics and optimal childbearing, improved patient experiences, and greater public awareness and acceptance, there remains substantial room for future growth in ART penetration, making it a key area of interest for investors. Jinxin Fertility (01951.HK), the largest private ART provider in China, operates within this major sector and has demonstrated strong post-IPO performance, with its share price doubling and recording an 80% increase over the past three months.

Beikang Medical, a leading enterprise with core technological strengths in the field of genetic testing for assisted reproduction, has been deeply engaged in the industry for 11 years. It has built an industrial chain covering the entire reproductive cycle centered on embryo testing, forming a product testing system for pre-conception, prenatal, and neonatal stages. Its independently developed PGT-A test kit is the first and currently the only third-generation IVF genetic testing kit registered with the National Medical Products Administration (NMPA) and commercialized in China. The PGT-M kit achieves universal detection of embryonic genetic defects through multiplex PCR technology innovation, while the PGT-SR kit overcomes the challenge of screening for embryonic chromosomal structural rearrangements through underlying enzyme innovation. The PGT-M and PGT-SR kits are expected to receive NMPA registration approval in 2022 and 2024, respectively. Together with the existing PGT-A kit, they form a complementary and complete series of pre-conception test kits.

With its domestically pioneering and internationally leading technology, Beikang Medical has pioneered the field and niche market of third-generation IVF testing in China, participated in the formulation of national standards in this field, and represents the highest level in the field of third-generation IVF testing. For long-term investment institutions laying out the Chinese assisted reproduction track, Beikang Medical is undoubtedly an excellent choice. According to the prospectus, Hillhouse Hong Kong, under Hillhouse Capital, holds a 6.82% stake in Beikang Medical. This deep industrial layout by Hillhouse Capital fully reflects its affirmation of the Chinese assisted reproduction industry market.